UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ASCENDIS PHARMA A/S,
Petitioner,

v.

BIOMARIN PHARMACEUTICAL INC.,
Patent Owner.

Case PGR2026-00013
Patent No. 12,233,106 B2

PATENT OWNER'S CURRENT LIST OF EXHIBITS

LIST OF EXHIBITS

Exhibit No.	Description	Previously Submitted
2001	USITC Inv. No. 337-TA-1447, Order No. 25: Amending Procedural Schedule (December 16, 2025), EDIS Doc. ID. 866614	X
2002	USITC Investigations Database System, Status of Investigation 337-1447, https://ids.usitc.gov/case/8276/investigation/8728 (last accessed January 20, 2026)	X
2003	RESERVED	
2004	U.S. Reissue Patent No. 48,267	X
2005	USITC Inv. No. 337-TA-1447, Amended Complaint (August 22, 2025), EDIS Doc. ID. 860269	X
2006	USITC Inv. No. 337-TA-1447, Disputed and Agreed Claim Constructions (September 23, 2025), EDIS Doc. ID 862675	X
2007	USITC Inv. No. 337-TA-1447, Respondents' Opening Claim Construction Brief (publicly available Feb. 5, 2026) (EDIS Doc No. 871764)	
2008	USITC Inv. No. 337-TA-1447, Respondents' Reply Claim Construction Brief (publicly available Feb. 5, 2026) (EDIS Doc. ID No. 871767)	
2009	RESERVED	
2010	RESERVED	
2011	USITC Inv. No. 337-TA-1447, Order No. 15: Initial Determination Granting Complainant's (1) Motion to Declassify and (2) Motion to Amend the Complaint and Notice of Investigation (August 14, 2025), EDIS Doc. ID. 861044	X
2012	FDA Guidance for Industry, General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products (July 2022) at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-clinical-pharmacology-considerations-neonatal-studies-drugs-and-biological-products-guidance, and	X

	https://www.fda.gov/media/129532/download (last accessed January 27, 2026)	
2013	Sian Gaze, Best Practice for Medicines Use in Neonates, Pharmaceutical Journal (May 7, 2024) at https://pharmaceutical-journal.com/article/ld/best-practice-for-medicines-use-in-neonates (last accessed January 27, 2026)	X
2014	March 31, 2025 Ascendis Press Release at https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-submits-us-nda-transcon-cnp-navepegritide-treatment (last accessed January 27, 2026)	X
2015	November 25, 2025 Ascendis Press Release at https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-announces-extension-fda-review-period-transcon-cnp (last accessed January 27, 2026)	X
2016	Clinical Trial NCT06079398 (ASND0030) at https://clinicaltrials.gov/study/NCT06079398 (last accessed January 27, 2026)	X
2017	Savarirayan (2024), *Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial*, Lancet Child Adolesc. Health, 8(1):40-50	X
2018	USITC Inv. No. 337-TA-1447, Commission Investigative Staff's Claim Construction Brief (December 1, 2025), EDIS Doc. ID. 866257	X

Dated: March 12, 2026

Respectfully submitted,

By: /Naveen Modi/
Naveen Modi
Reg. No. 46,224

CERTIFICATE OF SERVICE

I certify that I caused to be served on the counsel identified below a true and correct copy of the foregoing Patent Owner's Current List of Exhibits by electronic means on March 12, 2026:

David H. Homan (dholman-PTAB@sternekessler.com)
Pratibha Khanduri (pkhanduri-PTAB@sternekessler.com)
Olga A. Partington (opartington-PTAB@sternekessler.com)
Eric Steffe (esteffe-PTAB@sternekessler.com)
PTAB@sternekessler.com

By: /Naveen Modi/
Naveen Modi
Reg. No. 46,224